259 related articles for article (PubMed ID: 33656637)
1. The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
Smith SG; Sestak I; Morris MA; Harvie M; Howell A; Forbes J; Cuzick J
Breast Cancer Res Treat; 2021 Jul; 188(1):215-223. PubMed ID: 33656637
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
[TBL] [Abstract][Full Text] [Related]
4. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Cawthorn S; Mansel RE; Loibl S; Bonanni B; Evans DG; Howell A;
Lancet; 2020 Jan; 395(10218):117-122. PubMed ID: 31839281
[TBL] [Abstract][Full Text] [Related]
5. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M
Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530
[TBL] [Abstract][Full Text] [Related]
6. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Sestak I; Smith SG; Howell A; Forbes JF; Cuzick J
Ann Oncol; 2018 Feb; 29(2):504-509. PubMed ID: 29126161
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
8. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Sestak I; Harvie M; Howell A; Forbes JF; Dowsett M; Cuzick J
Breast Cancer Res Treat; 2012 Jul; 134(2):727-34. PubMed ID: 22588672
[TBL] [Abstract][Full Text] [Related]
9. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Sestak I; Distler W; Forbes JF; Dowsett M; Howell A; Cuzick J
J Clin Oncol; 2010 Jul; 28(21):3411-5. PubMed ID: 20547990
[TBL] [Abstract][Full Text] [Related]
10. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Jenkins VA; Ambroisine LM; Atkins L; Cuzick J; Howell A; Fallowfield LJ
Lancet Oncol; 2008 Oct; 9(10):953-61. PubMed ID: 18768369
[TBL] [Abstract][Full Text] [Related]
11. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
13. Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Juraskova I; Butow P; Lopez A; Seccombe M; Coates A; Boyle F; McCarthy N; Reaby L; Forbes JF
Health Expect; 2008 Sep; 11(3):252-62. PubMed ID: 18816321
[TBL] [Abstract][Full Text] [Related]
14. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
; Forbes JF; Cuzick J; Buzdar A; Howell A; Tobias JS; Baum M
Lancet Oncol; 2008 Jan; 9(1):45-53. PubMed ID: 18083636
[TBL] [Abstract][Full Text] [Related]
15. Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial.
Pegington M; Zhen Tam H; Brentnall A; Sestak I; Adams J; Blake GM; Gareth Evans D; Howell A; Cuzick J; Harvie M
Prev Med Rep; 2024 Feb; 38():102620. PubMed ID: 38375161
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
18. [Body mass index and cancer incidence:a prospective cohort study in northern China].
Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
20. Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women.
; Schoemaker MJ; Nichols HB; Wright LB; Brook MN; Jones ME; O'Brien KM; Adami HO; Baglietto L; Bernstein L; Bertrand KA; Boutron-Ruault MC; Braaten T; Chen Y; Connor AE; Dorronsoro M; Dossus L; Eliassen AH; Giles GG; Hankinson SE; Kaaks R; Key TJ; Kirsh VA; Kitahara CM; Koh WP; Larsson SC; Linet MS; Ma H; Masala G; Merritt MA; Milne RL; Overvad K; Ozasa K; Palmer JR; Peeters PH; Riboli E; Rohan TE; Sadakane A; Sund M; Tamimi RM; Trichopoulou A; Ursin G; Vatten L; Visvanathan K; Weiderpass E; Willett WC; Wolk A; Yuan JM; Zeleniuch-Jacquotte A; Sandler DP; Swerdlow AJ
JAMA Oncol; 2018 Nov; 4(11):e181771. PubMed ID: 29931120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
